Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sorafenib + YIV-906
- Development stage
- Phase 2
- Lead developer
- Yiviva
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Sorafenib + YIV-906 is a combination therapy being developed by Yiviva Inc. for the treatment of advanced hepatocellular carcinoma (HCC), particularly in patients with chronic hepatitis B (HBV+). YIV-906 (formerly PHY906 or KD018) is an orally administered botanical drug candidate composed of a patented extract of four herbs, inspired by an 1800-year-old traditional Chinese medicine (Huang Qin Tang). It acts as a pan-adjuvant and immune system modulator designed to enhance the anti-tumor activity of cancer drugs while protecting the gastrointestinal tract from toxicity by reducing inflammation and promoting tissue regeneration. Sorafenib is a multi-kinase inhibitor that targets VEGFR, PDGFR, and Raf kinases to inhibit tumor cell proliferation and angiogenesis. The combination is currently being evaluated in the Phase 2b CALM trial (NCT04000737) and has received Orphan Drug Designation from the FDA for hepatocellular carcinoma and pancreatic cancer.
- Brand names
- Nexavar
- Other names
- sorafenib plus YIV-906PHY906 plus sorafenibPHY-906 plus sorafenibPHY 906 plus sorafenib
02
Targets
BRAF (B-Raf proto-oncogene, serine/threonine kinase)DUSP3DUSP5 (Dual specificity protein phosphatase 5)DUSP7FLT3 (Fms related receptor tyrosine kinase 3)VEGFR4 (Vascular endothelial growth factor Receptor-3)HTR2A (5-hydroxytryptamine receptor 2A)HTR2B (5-Hydroxytryptamine Receptor 2B)HTR2C (5-hydroxytryptamine 2C receptor)VEGFR2 (Vascular endothelial growth factor receptor 2)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRB (Platelet-derived growth factor receptor beta)PTPN11 (Tyrosine-protein phosphatase non-receptor type 11)PTPN6 (Protein tyrosine phosphatase non-receptor type 6)RAF1 (c-Raf-1 (Y340D/Y341D))VEGFR-1 (Vascular endothelial growth factor receptor 1)
Beyond the preview
Go deeper on sorafenib + YIV-906.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sorafenib + YIV-906.